Abide Therapeutics in the News

View All News

Abide Continues Support of the Tourette Community Through Collaboration with Tourette Association of America

Company Announcement
April 09, 2019

In continuation of our collaboration with the Tourette Association of America (TAA) begun in 2017, Abide Therapeutics has renewed our commitment to partnering with the TAA to gain a better understanding of the unmet needs in the Tourette community.

As we continue to explore the potential utility of ABX-1431, our lead product candidate, in Tourette Syndrome (TS), we are grateful for the opportunity to partner with the TAA to further understand the challenges faced by those affected by the condition. By participating in the upcoming TAA Annual Research and Medical Meeting of the SAB, MAB, and Centers of Excellence, we have the opportunity to learn from the healthcare practitioners who treat patients with TS every day, including understanding the gaps in the current treatment landscape and how Abide could help fill them.

ABX-1431 has shown promising clinical data in a Phase 1b placebo-controlled trial in patients with TS, achieving statistical significance on multiple clinical endpoints such as reducing the number of tics experienced and reducing the urge to tic. Based on these results, Abide began a Phase 2 trial with ABX-1431 in adult TS in 2018.

“We are pleased to continue our partnership with Abide Therapeutics as the Tourette Syndrome community needs more companies focused on developing new treatments for Tourette,” said Amanda Talty, President and CEO of the Tourette Association of America. “With no existing cure for Tourette Syndrome, there is a critical need for safe and effective treatment options. We look forward to working together in our shared mission of improving the quality of life of all individuals affected by Tourette Syndrome.”

Tourette Syndrome is a neuropsychiatric disorder that first appears during childhood. People with TS experience sudden, involuntary, repetitive movements and vocalizations called tics. The tics may be preceded by an uncomfortable feeling or sensation called a premonitory urge. This urge may allow patients to suppress their tics, but suppression may worsen the urge.

About ABX-1431

ABX-1431 is a first-in-class, investigational oral therapy designed to inhibit monoacylglycerol lipase (MGLL), an enzyme that regulates a key system that serves as a natural brake on excessive brain signaling. Inhibition of MGLL by ABX-1431 may potentiate putting the brakes on overactive neural circuits. This may serve to correct abnormal neurotransmission, which is often dysregulated in neurological diseases. Abide is currently testing ABX-1431 in clinical trials for the treatment of Tourette Syndrome and other neurological diseases.

About Abide Therapeutics

Abide Therapeutics is focused on developing first-in-class drugs for serious diseases with significant unmet medical need. An innovative discovery platform and a library of proprietary small molecules allow Abide to address biological pathways with potential therapeutics that enhance the body’s normal physiological response to disease. The platform enables Abide to efficiently identify, develop, and validate small-molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide’s lead program focuses on addressing neurological diseases with limited treatment options through the inhibition of the serine hydrolase monoacylglycerol lipase (MGLL). Abide has offices in San Diego, California and Princeton, New Jersey. To learn more, visit www.abidetx.com.

Media Contact

Patty Pilon
Abide Therapeutics
Tel: +1 619.244.2679